Recent 8-K filings for DSGN

• May 18, 2026, 7:15 AM ET other material materiality 0.80 positive item 8.01

  Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia

  After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).

• March 9, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029

  Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.

• November 5, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M

  DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M

  Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.

• May 7, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029

  R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.

• March 10, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing

  Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.

• August 5, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track

  Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event earnings

2 positive 0 negative 14 neutral

source · DSGN on sec.gov